Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109330 · ClinicalTrials.gov registry record · Phase 3
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,116
- Enrollment target
NCT00109330: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00109330 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 4,116 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (433% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00109330, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,116 participants
- Enrollment target
Study Summary
This study will evaluate the safety and immune response to GlaxoSmithKline Tdap vaccine compared to licensed Td vaccine when used as a booster in healthy adolescents (10-18 years of age).
Interventions
- BIOLOGICAL Combined diphtheria, tetanus, acellular pertussis vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,116 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-04 |
| Phase | Phase 3 |
What the finished NCT00109330 record still lists
NCT00109330 is an interventional study that assigns participants to a tested intervention. Its 4,116 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (433% higher).
The record links to 0 conditions, and to 1 intervention - of which Combined diphtheria, tetanus, acellular pertussis vaccine is the first listed.
NCT00109330 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00109330 about?
NCT00109330 is a clinical study titled "A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine". This study will evaluate the safety and immune response to GlaxoSmithKline Tdap vaccine compared to licensed Td vaccine when used as a booster in healthy adolescents (10-18 years of age).
What is the current status of trial NCT00109330?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,116 participants. The study started on 2002-11. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00109330?
The interventions under investigation include: Combined diphtheria, tetanus, acellular pertussis vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00109330?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00109330's enrollment target sits among peer trials
4,116 61st of 2000 higher than 1,940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03388606 · 4,100 participants
Characterization and Treatment of Adolescent Depression
- NCT06593353 · 4,165 participants · NA
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
- NCT02693535 · 4,200 participants · Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- NCT05969028 · 4,200 participants · NA
First Responder Airway & Compression Rate Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia